{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:42:51Z","timestamp":1781905371272,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108748","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:45:16Z","timestamp":1757335516000},"page":"108748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real\u2013world study"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-5109","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-0634","authenticated-orcid":false,"given":"Steven H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-1027","authenticated-orcid":false,"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jii Bum","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-9334","authenticated-orcid":false,"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2000-7472","authenticated-orcid":false,"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-9867","authenticated-orcid":false,"given":"Maria","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0016-6550","authenticated-orcid":false,"given":"Feruza","family":"Nasirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3055-9943","authenticated-orcid":false,"given":"YongJin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108748_b0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/thoraxjnl-2012-202297","article-title":"Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007","volume":"68","author":"Walters","year":"2013","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108748_b0010","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/jcm11061738","article-title":"Real-world journey of unresectable stage III NSCLC patients: current dilemmas for disease staging and treatment","volume":"11","author":"Agbarya","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108748_b0015","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3747\/co.27.6047","article-title":"Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108748_b0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4143\/crt.2018.125","article-title":"EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2025.108748_b0025","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","article-title":"Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations","volume":"167","author":"Riudavets","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108748_b0030","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/jrr\/rrw075","article-title":"The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis","volume":"57","author":"Ochiai","year":"2016","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.lungcan.2025.108748_b0035","unstructured":"U.S. Food and Drug Administration, FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC, 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc."},{"issue":"20","key":"10.1016\/j.lungcan.2025.108748_b0040","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108748_b0045","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2025.108748_b0050","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO-24-01324","article-title":"Management of stage III non\u2013small cell lung cancer: ASCO Guideline Rapid Recommendation Update","volume":"42","author":"Daly","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108748_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R Study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108748_b0060","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108748_b0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: a post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108748_b0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108748_b0075","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108748_b0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108748_b0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2025.108748_b0090","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.lungcan.2025.108748_b0095","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108748_b0100","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","author":"Reungwetwattana","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108748_b0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108748_b0110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann. Oncol."},{"issue":"36","key":"10.1016\/j.lungcan.2025.108748_b0115","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1200\/JCO-24-02133","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2024.2","volume":"42","author":"Bazhenova","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108748_b0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108748_b0125","unstructured":"U.S. Food and Drug Administration, FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-locally-advanced-unresectable-stage-iii-non-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2025.108748_b0130","unstructured":"AstraZeneca PLC, Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer, 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/tagrisso-recommended-for-eu-approval-laura.html."},{"key":"10.1016\/j.lungcan.2025.108748_b0135","unstructured":"ESMO oncogene-addicted metastatic non-small-cell lung cancer Living Guidelines, v1.1 July 2024, 2024. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-oncogene-addicted-metastatic-non-small-cell-lung-cancer."},{"key":"10.1016\/j.lungcan.2025.108748_b0140","author":"European Medicines Agency","year":"2025","journal-title":"Tagrisso (osimertinib)"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108748_b0145","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","article-title":"Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study","volume":"35","author":"Lu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108748_b0150","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1556-0864(25)00379-X","article-title":"Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): updated overall survival (OS) analysis from the LAURA study","volume":"20","author":"Ramalingam","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108748_b0155","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: a multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108748_b0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"Lindeman","year":"2018","journal-title":"J. Mol. Diagn."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108748_b0165","doi-asserted-by":"crossref","first-page":"790","DOI":"10.6004\/jadpro.2022.13.8.5","article-title":"Liquid biopsy for guiding treatment decisions in advanced non-small cell lung cancer","volume":"13","author":"Suk","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108748_b0170","doi-asserted-by":"crossref","first-page":"594","DOI":"10.21037\/tlcr-22-742","article-title":"Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review","volume":"12","author":"Tomasik","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108748_b0175","doi-asserted-by":"crossref","first-page":"S326","DOI":"10.1016\/j.jtho.2024.09.585","article-title":"Concordance of liquid biopsy and tissue biopsy for the detection of EGFR mutation in stage III NSCLC in the United States","volume":"19","author":"Malapelle","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"suppl 4","key":"10.1016\/j.lungcan.2025.108748_b0180","doi-asserted-by":"crossref","first-page":"S1626","DOI":"10.1016\/j.annonc.2024.10.646","article-title":"Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): post-progression outcomes from the phase III LAURA study","volume":"35","author":"Ozguroglu","year":"2024","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T09:08:37Z","timestamp":1763111317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"alternative-id":["S0169500225006403"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108748","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real\u2013world study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108748"}}